T cell responses must be balanced to ensure adequate protection against malignant
transformation and an array of pathogens while also limiting damage to healthy cells and …

Immune checkpoint blockade (ICB) has become a promising strategy in treating advanced
cancers, providing significant survival benefits for patients with various cancer types …

Background IGV-001 is a personalized, autologous cancer cell-based immunotherapy
conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory …

Rationale: Novel immune-activating therapeutics for the treatment of glioblastoma
multiforme (GBM) have shown potential for tumor regression and increased survival over …

Background Lower respiratory infections are a leading cause of severe morbidity and
mortality among older adults. Despite ubiquitous exposure to common respiratory …

Type I interferons have long been appreciated as a cytokine family that regulates antiviral
immunity. Recently, their role in eliciting antitumor immune responses has gained increasing …

Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing
durable remissions in responding patients. However, they are associated with variable …

Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However,
clinical trials of various immunotherapeutic modalities have not yielded significant …

In situations involving continuous exposure to antigens, such as chronic infections or cancer,
antigen‐specific CD8+ T cells can become dysfunctional or exhausted. This change is …

Background The GL261 and CT2A syngeneic tumor lines are frequently used as
immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but …